guest ::
| Home > Publications database > The immunology of brain tumors. |
| Home > Publications database > The immunology of brain tumors. |
| Journal Article (Review Article) | DKFZ-2025-02040 |
; ; ; ;
2025
AAAS
Washington, DC
This record in other databases: 
Please use a persistent id in citations: doi:10.1126/sciimmunol.ads0449
Abstract: Brain tumors represent a unique challenge for cancer immunotherapies because of their location in an immune privileged site. However, the brain tumor immune microenvironment is dictated more by tumor type than the location within the brain per se. This feature is reflected by the higher immunogenicity and response to immunotherapies of metastatic brain tumors compared with primary brain tumors. Immunotherapies for brain tumors aim at inducing and boosting tumor T cell responses using vaccines, immune checkpoint inhibitors, or adoptive T cell therapies. A fundamental challenge in the field is how such brain tumor-targeting T cells gain access to brain tumors and maintain their function despite a hostile immunosuppressive microenvironment. Here, we review current knowledge of the cellular and molecular determinants of the antigenicity of brain tumors and the immunosuppressive brain tumor microenvironment. Expanding and exploiting this knowledge will provide the key for effective combinatorial therapies.
Keyword(s): Humans (MeSH) ; Brain Neoplasms: immunology (MeSH) ; Brain Neoplasms: therapy (MeSH) ; Tumor Microenvironment: immunology (MeSH) ; Animals (MeSH) ; Immunotherapy: methods (MeSH) ; T-Lymphocytes: immunology (MeSH) ; Cancer Vaccines: immunology (MeSH) ; Cancer Vaccines
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Essential Science Indicators ; IF >= 20 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
